Our study reveals that the administration of semaglutide to leptin receptor-deficient hyperphagic diabetic mice results in the amelioration of MASLD, likely independent of food intake, suggesting a direct effect of semaglutide on the liver. This evidence concerns the gene LEPR and metabolic dysfunction-associated steatotic liver disease.